---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-154057"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:24:34.011315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share

## Summary
- Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).
- Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.
- Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital.

## SEC filing metadata
- accession: 0001193125-25-154057
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/0001193125-25-154057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/d38498d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-154057
- JSON: https://secwatch.observer/filing/0001193125-25-154057.json
- Plain text: https://secwatch.observer/filing/0001193125-25-154057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.